The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

Human norovirus, a positive-strand RNA virus that is the leading cause of viral gastroenteritis accounting for an estimated 685 million cases and approximately 212,000 deaths globally per year, has no ...

Single-cell analysis helps uncover how the BK virus replicates, opening the door to new drug targets. BK polyomavirus (BKPyV) is a major cause of kidney transplant failure. Without a complete ...

Forget about locating molecules in the blink of an eye, which takes as long as a quarter second—far too long a time to distinguish a sequence of subcellular events. Instead, try doing what Stanford ...

For the first time, scientists have captured how new antiviral drugs halt the herpes virus in real time as it tries to ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...